Benton Franklin County Medical Society 31st Annual CME Seminar

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Benton Franklin County Medical Society 31st Annual CME Seminar"

Transcription

1 Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier, MD Endocrinologist Spokane, WA

2 Management of Current HT/ET and SERM Recommendations Lynn Kohlmeier, MD Impact and Consequences of Estrogen Loss History of Estrogen + Progesterone (EPT or HT) and Estrogen alone (ET) WHI Affect Safety Post-WHI Cardiac/Vascular Breast Endometrium Bone Selective Estrogen Receptor Modulator (SERM) SuperSERM or Tissue Selective Estrogen (TSE) 2

3 Management of Current HT/ET (Consequences of Estrogen Loss) Skin dryness and Aging Vasomotor symptoms Hot flashes Sleep disturbance Cardiovascular disease Urogenital atrophy Osteoporosis

4 History of Hormone Therapy (Pro-Estrogen and Anti-Estrogen Camps) s s First published paper on treating severe climacteric symptoms Preventing climacteric syndrome with estrogen first mentioned Wilson s Feminine forever published; increased endometrial cancer First commercial estrogen preparations become available CE introduced as a treatment for hot flushes and sleep disturbances Progestins added to protect the endometrium van Keep PA. Maturitas. 1990;12: Kopera H, et al. Intl J Clin Pharmacol, Ther Toxicol. 1991;29(10): slide compliments of Risa Kagan, M 4

5 Management of Current HT/ET Recommendations PRE-WHI MIRACLE DRUG CURES Hot Flashes Reduces Osteoporosis Reduces Heart Disease Decreases Wrinkles Improves Cognition Enhances Well-Being slide compliments of Risa Kagan, MD 5

6 *from primate Slide atherosclerosis compliments studies of Brad Hurst, MD Management of Current HT/ET Recommendations Estrogen before plaque >>> prevents plaque* Estrogen after plaque >>> accelerates plaque*

7 Management of Current HT/ET and SERM Recommendations Spokane steoporosis Dr. Lynn Kohlmeier

8 FDA- Approved Angeliq (drospirenone and estradiol) Alora (estradiol transdermal system) Climara (estradiol transdermal system) Climara Pro (estradiol/levonorgestrel transdermal system) Combipatch (estradiol; norethindrone acetate transdermal system) Delestrogen (estradiol valerate injection) Duavee (basodoxifene/cee, SuperSERM/TSE) Enjuvia (synthetic conjugated estrogens; B) Estraderm (estradiol transdermal system) Estrasorb (estradiol topical emulsion) Evista (raloxifene, SERM) Femhrt (norethindrone acetate/ethinyl estradiol tablets) Femring (estradiol acetate vaginal ring) Prefest (estradiol/norgestimate) Tablets Premarin (conjugated estrogens tablets) Premarin Intravenous (conjugated estrogens, USP for injection) Vivelle (estradiol transdermal system) Vivelle-Dot (estradiol transdermal system) Premarin Vaginal Cream (conjugated estrogens) PREMPRO/PREMPHASE (conjugated estrogens/ medroxyprogesterone acetate tablets) 8 Spokane steoporosis Dr. Lynn Kohlmeier

9 History of Hormone Therapy (Disease Prevention) 1991 WHI Established 2002 WHI E+P (HT) Arm Halted 2004 FDA Treatment Recommendations WHI E-Only Arm Ended WHI Trial: 3 Components Randomized Clinical Trial Observational Study Community Prevention Study slide compliments of Risa Kagan, MD

10 History of Hormone Therapy (WHI Trial Design) YES N= 10,739 Hysterectomy NO N= 16,608 Conjugated equine estrogen (CEE) mg/d (E alone) Placebo CEE mg/d + medroxyprogesterone acetate (MDA) 2.5mg/d (E + P or HT) Placebo slide compliments of Risa Kagan, MD 10

11 Management of Current HT/ET Recommendations POST-WHI DANGER DRUG CURES Hot Flashes Reduces Osteoporosis Enhances Well-Being Reduces Colon Cancer?? Heart Disease?? Breast Disease slide compliments of Risa Kagan, MD 11

12 WHI Outcomes with HT/Prempro Overall Outcomes With PREMPRO Reported From the WHI - Annualized Attributable Risk per 1,000 Women Change in Annual Events per 1,000 Women * Invasive Breast Cancer 1 * Stroke VTE CHD2-0.1 Endometrial Cancer 4 NS = statistically nonsignificant change; VTE = venous thromboembolism, CHD = coronary heart disease *Nominal confidence intervals significant (adjusted confidence intervals not shown). No adjudicated data available. 1. Anderson GL, et al. Maturitas. 2006;55: Rossouw JE, et al. JAMA. 2007;297: Cushman M, et al. JAMA. 2004;292: Anderson GL, et al. JAMA. 2003;290: * NS NS -0.6 * Colorectal Cancer * Hip Fractures * Vertebral Fractures 6 12

13 WHI Outcomes with HT/Prempro WHI E+P Substudy Risk by Age Attributable risk per 1,000 women Number of Events CHD 1 Stroke Colorectal cancer Invasive breast cancer 3 VTE 5 Hip fracture 3.5 * Placebo (Baseline Risk) -5 Age Age Age *Significance by hazard ratio and 95% confidence interval compared with placebo. Significance by hazard ratio and 95% confidence interval compared with year old women taking placebo. 1. Rossouw JE, et al. JAMA. 2007;297: Chlebowski RT, et al. JAMA. 2003;289: Cushman M, et al. JAMA. 2004;292: Chlebowski RT, et al. N Engl J Med. 2004;350: Cauley JA, et al. JAMA. 2003;290:

14 WHI Outcomes with ET/Premarin Overall Risks With PREMARIN Reported From the WHI: Annualized Attributable Risk per 1,000 Women Change in Annual Events per 1,000 Women NS -0.6 Invasive Breast Cancer 1 * NS NS -0.3 Stroke 2 VTE 3 CHD NS Colorectal Cancer * Hip Fractures 5 * Vertebral Fractures 5 Placebo (Baseline Risk) NS = statistically nonsignificant change; VTE = venous thromboembolism; CHD = coronary heart disease. *Nominal P<0.05 vs. placebo (adjusted confidence intervals not shown). The risk of VTE (deep vein thrombosis [DVT] and pulmonary embolism) was reported to be increased for women receiving daily CE compared with placebo, although only the increased risk of DVT reached statistical significance. The increase in VTE risk was demonstrated during the first 2 years. 1. Stefanick ML, et al. JAMA. 2006;295: Rossouw JE, et al. JAMA. 2007;297: Curb JD, et al. Arch Intern Med. 2006;166: Ritenbaugh C, et al. Cancer Epidemiol Biomarkers Prev. 2008;17:

15 WHI Outcomes with ET/Premarin WHI E-Alone Substudy Risk by Age Attributable risk per 1,000 women 5 1 CHD 1 Stroke Colorectal cancer 2 Invasive breast cancer 3 VTE 4 Hip fracture 2 Number of Events * Age Age Age *Significance by hazard ratio and 95% confidence interval compared with placebo. Significance by hazard ratio and 95% confidence interval compared with year old women taking placebo * -2.1 * Placebo (Baseline Risk) No significant age interaction for VTE. 1. Rossouw JE, et al. JAMA. 2007;297: Women's Health Initiative Steering Committee. JAMA. 2004;291: Curb JD, et al. Arch Intern Med. 2006;166: Jackson RD, et al. J Bone Miner Res. 2006;21:

16 Post WHI: Challenges of ET/HT Clinician Time Constraints Buzz about Bioidenticals & Alternatives Women Need Individualized Treatment Media Impact Public s Understanding of HT Risks & Benefits slide compliments of Risa Kagan, MD 16

17 Management of Current HT/ET Recommendations A Decade After The Women s Health Initiative The Experts Do Agree Statement was published in North American Menopause Society (Menopause), American Society for Reproductive Medicine (Fertility and Sterility), and Endocrine Society (Journal of Clinical Endocrinology and Metabolism) 17 slide compliments of Risa Kagan, MD

18 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Vasomotor Symptoms ET with or without progestogen is most effective treatment of menopause-related vasomotor symptoms Almost all systemic HT products are approved for vasomotor symptom relief Vaginal Symptoms ET is most effective treatment of moderate to severe symptoms of vulvar and vaginal atrophy Many systemic HT and local vaginal ET products available for treating these symptoms 18

19 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Sexual Function Low-dose local ET may improve sexual function by improving lubrication and increasing blood flow HT is not recommended as sole treatment of other sexual function problems (eg, diminished libido) Urinary Tract Health Local ET benefit women with overactive bladder Only vaginal ET effective for urinary tract infection Systemic ET may worsen or provoke stress incontinence Ultralow-dose transdermal ET has no effect on incontinence 19

20 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Osteoporosis HT reduced the risk for fracture (eg, hip, spine, nonspine) in postmenopausal women in the Women s Health Initiative (WHI) who were not selected on basis of osteoporosis Many systemic HT products are approved for preventing postmenopausal osteoporosis No HT product is approved for treating osteoporosis Extended use of HT is option for women at high risk of osteoporotic fracture when alternate therapies aren t appropriate Risks of long-term HT use should be considered Benefits of HT on bone mass dissipate quickly after discontinuation 20

21 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Coronary Heart Disease ET may reduce CHD and coronary artery risk when initiated in younger and more recently postmenopausal women without a uterus HT is currently not recommended for coronary protection in women of any age Stroke Both ET and HT appear to increase ischemic stroke risk and have no effect on hemorrhagic stroke risk 21

22 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Venous Thromboembolism Oral HT increases the risk of VTE in postmenopausal women VTE risk emerges soon after HT initiation (1-2 y) and decreases over time Lower VTE risk with either EPT or ET in women before age 60 Possible lower VTE risk with transdermal and lower oral HT doses. No RCT evidence 22

23 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Endometrial Cancer Unopposed systemic ET in postmenopausal women with an intact uterus is associated with increased endometrial cancer related to dose/duration of use HT not recommended with history of endometrial cancer history Breast Cancer Diagnosis of breast cancer increases with HT use beyond 3-5 years Unclear whether HT risk differs between continuous and sequential progestogen HT and to a lesser extent ET increase breast cell proliferation, breast pain, and mammographic density 23

24 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Breast Cancer HT may impede diagnostic interpretation of mammograms Breast cancer diagnosis dissipated 3 years post HT cessation Breast cancer mortality higher in women assigned to HT compared to placebo Women starting HT shortly after menopause experience increased breast cancer risk, but those with a gap time greater than 5 years do not ET arm of WHI showed no increased cancer risk after mean 7.1 years on study ET and HT use in breast cancer survivors may increase recurrence risk

25 Management of Current HT/ET Benefits & Risks Mood and Depression NAMS position statement. Menopause 2012 Evidence is mixed on effect of HT on mood when no clinical depression Progestogens in EPT may worsen mood when history of PMS, PMDD, or clinical depression HT should not be recommended as an antidepressant Cognitive Aging/Dementia Evidence is mixed on effect of HT on cognition at time of menopause with no effect on episodic memory or executive function with ET at time of menopause WHI Memory Study in HT use ages an increase in dementia was reported

26 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Premature Menopause/ Premature Ovarian Insufficiency Data regarding HT in women over age 50 should not be extrapolated to younger postmenopausal women Likely risks attributable to HT are smaller and benefits greater in younger women Use of HT or OCPs until median age of menopause is recommended at which time decision reevaluated Total Mortality HT may reduce total mortality when initiated soon after menopause ET and HT may reduce total mortality by 30% when initiated in women younger than age 60

27 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Practical Therapeutic Issues Well-tested, government-approved, brand-name HT/ET products contain hormones chemically identical to those made by ovaries Bioidentical Hormone Therapy BHT usually refers to custom-compounded formulations marketed as more natural or bioidentical BHT should include package inserts explaining benefits & risks just like government-approved HT/ET products

28 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Dose & Route of Administration Therapeutic goal is lowest effective estrogen dose consistent with individual treatment goals, benefits, and risks, plus progestogen for women with a uterus Lower doses have fewer side effects and may have more favorable benefit-risk ratio than standard doses but lower doses not been tested in long-term trials All routes of administration effectively treat symptoms Non-oral routes may offer both advantages and disadvantages compared with oral route (no RCTs) Transdermal ET may be associated with lower risk of DVT, stroke, and MI

29 Management of Current HT/ET Benefits & Risks NAMS position statement. Menopause 2012 Bioidentical Hormone Therapy (BHT) Custom BHT may combine several hormones and use nonstandard routes of administration Use of compounded BHT and salivary hormone testing are not recommended BHT is not tested for efficacy, safety, batch standardization, or purity FDA says compounding pharmacies make false and misleading claims about safety/effectiveness of BHT Compounded HT should only be used by women allergic to ingredients in approved products

30 Management of Current HT/ET Treatment Duration of Use HT increases risk of breast cancer incidence and mortality with 3-5 years of use ET poses no increase of breast cancer with early postmenopausal use; decrease found after hiatus in estrogen exposure With ET, potential CAD/CHD benefits with early use Initial increase in CHD risk when HT is initiated further from menopause Extending HT acceptable for: NAMS position statement. Menopause 2012 Women who request it and well aware of potential risks/benefits Prevention of further osteoporosis-related fracture and bone loss when alternate therapies are not appropriate or cause unacceptable adverse effects

31 Management of Current HT/ET Treatment NAMS position statement. Menopause 2012 Discontinuation All-cause mortality neutral for both Symptom recurrence similar whether tapered or abruptly discontinued After 3 years of ET discontinuation: - No increase in CHD, DVT, stroke, hip fracture, colorectal cancer, or total mortality - Decrease in breast cancer persisted After 3 years of HT discontinuation: - Rate of cardiovascular events, fractures, and colon cancer same as placebo group - Increase in rate of all cancers and mortality from breast cancer

32 Management of Current HT/ET Treatment NAMS position statement. Menopause 2012 Conclusions & Recommendations Individualization is key in decision to use HT and should incorporate the woman s health and QOL priorities as well as her personal risk factors for VTE, CHD, stroke, and breast cancer Duration recommendations differ for HT and ET: Use of HT is limited by risk of breast cancer and breast cancer mortality after 3-5 years Use of ET is more favorable with benefit-risk profile during mean of 7 years of use and 4 years of followup allowing more flexibility in duration of use

33 Management of Current HT/ET Treatment NAMS position statement. Menopause 2012 Conclusions & Recommendations ET is most effective for vulvar and vaginal atrophy Low-dose local vaginal ET advised for vaginal sxs Women with premature/early menopause can use HT until median age of menopause (51 y); longer duration can be considered for symptoms Although ET did not increase breast cancer risk in WHI, no safety data for breast cancer survivors, and RCT reported higher increase in recurrence Both transdermal and low-dose oral estrogen associated with lower risks of VTE and stroke but RCT evidence not yet available

34 SERM, Selective Estrogen Receptor Modulator, Raloxifene (Evista) Reduces bone resorption/turnover 60 mg oral daily now generic 30% in biochemical marker Approved for both prevention and treatment 2-3% BMD increases at hip & 3yrs Decreased incidence of vertebral fractures (30-50%) in women w preexisting vertebral fractures or low bone mass No effect on nonvertebral or hip fractures observed Adverse effects: Hot flashes, venous thrombosis, leg cramps Extra-skeletal effects: Reduction in invasive breast cancer No increase in stroke, MI or death Reduction in LDL Ettinger B, et al. JAMA. 1999;282:

35 First SuperSERM/TSE Benefits & Risks Duavee Approved Oct 2013 by the FDA pairs estrogen with a SERM rather than progestin, which helps prevent uterine lining thickening that can result from treatment with only estrogen CONJUGATED ESTROGEN (which help provide significant relief from moderate-to-severe hot flashes due to menopause and prevent bone loss) BAZEDOXIFENE (an estrogen agonist/antagonist, also known as a selective estrogen receptor modulator or SERM, which helps protect the uterine lining from the thickening that may occur in women who take estrogens alone) 35

36 First SuperSERM/TSE Benefits & Risks 36

37 First SuperSERM/TSE Skeletal Health Bazedoxifene, raloxifene (Evista), or placebo studied in 2-year randomized trial in 1583 postmenopausal women with low bone mass, T-score -1.0 to -2.5 Bazedoxifene or raloxifene similarly maintained spine and hip BMD, whereas women in the placebo group had significant bone loss at both sites (between group differences were 1.5 and 1.6%, respectively) Bazedoxifene (20 or 40 mg daily) or raloxifene (60 mg daily) in 3-year randomized trial in 6847 postmenopausal women with osteoporosis, T-score -2.5 or lower showed significant reductions in cumulative incidence of new vertebral fractures compared to placebo (fracture rates of 2.3, 2.5, 2.3 versus 4.1%) Risk of nonvertebral fractures were not decreased however in the raloxifene or bazedoxifene groups compared with controls

38 First SuperSERM/TSE Skeletal Health Duavee, BZA/CE, raloxifene, or placebo was studied in 3397 postmenopausal women with low bone density Lowest dose BZA (10 mg) combined with highest dose CE (0.625 mg) resulted in greatest increase in BMD In women > 5 years post menopause, formulations of BZA/CE containing BZA 10 or 20 mg with CE 0.45 or mg resulted in greater increases in spine BMD than raloxifene (between group difference 1.2 to 1.6%)

39 Management of Current HT/ET and SERM Recommendations A free mobile app for menopause symptom management from The North American Menopause Society Clinical decision-support tool Available for iphones and ipads Dual mode for Clinicians and Women/Patients Learn more at: Menopause 2015; 22(3):[e-pub 10/13/14] or at

40 Management of Current HT/ET and Spokane SERM Recommendations steoporosis Dr. Lynn Kohlmeier Risk/Benefit Analysis: Risk of a therapeutic intervention vs. Risk of not treating, balanced against the possible benefit of a therapy Thank You For Your Attention! Risk Benefit

North American Menopause Society (NAMS)

North American Menopause Society (NAMS) North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

SERMS, Hormone Therapy and Calcitonin

SERMS, Hormone Therapy and Calcitonin SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings

More information

Menopause. Medicines To Help You

Menopause. Medicines To Help You Medicines To Help You Menopause Use this guide to help you talk to your doctor, pharmacist, or nurse about your hormone medicines. The guide lists all of the FDA-approved products now available to treat

More information

Menopausal Symptoms The Who: Hot flashes are reported by as many as 75% of perimenopausal women in the U.S.

Menopausal Symptoms The Who: Hot flashes are reported by as many as 75% of perimenopausal women in the U.S. Menopausal Hormone Therapy: The Who, What, Where, When and Why Laurie Birkholz, MD, NCMP Knowledge of Clinical Trials Regarding Hormone Therapy and Likelihood of Prescribing Hormone Objective: The aim

More information

2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK

2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK 2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail

More information

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus)

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus) HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric

More information

Ms. Y. Outline. Updates of SERMs and Estrogen

Ms. Y. Outline. Updates of SERMs and Estrogen Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension

More information

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help

More information

Vol-5 No-1 Jan-Mar 2012

Vol-5 No-1 Jan-Mar 2012 "Women's Health" is also available at www.squarepharma.com.bd Editorial Board Dr. Omar Akramur Rab MBBS, FCGP, FIAGP Mohammad Hanif M. Pharm, MBA A.H.M. Rashidul Bari M. Pharm, MBA Executive Editor Chowdhury

More information

Estrogen and progestogen therapy in postmenopausal women

Estrogen and progestogen therapy in postmenopausal women Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone

More information

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and

More information

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,

More information

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,

More information

James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology

James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology

More information

Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD

Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,

More information

Appendix: Reference Table of HT Brand Names

Appendix: Reference Table of HT Brand Names Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

Menopausal Management: What Has Changed?

Menopausal Management: What Has Changed? Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning

More information

AusPharm CE Hormone therapy 23/09/10. Hormone therapy

AusPharm CE Hormone therapy 23/09/10. Hormone therapy Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of

More information

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy

More information

Menopause management NICE Implementation

Menopause management NICE Implementation Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not

More information

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now

More information

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists

More information

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013 Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort

More information

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review

More information

The Practice Committee of the American Society for Reproductive Medicine,

The Practice Committee of the American Society for Reproductive Medicine, FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen

More information

HRT: Neue Kombinationen

HRT: Neue Kombinationen HRT: Neue Kombinationen 4. Februar 2015 Gyndolomiti Cumulative Hazards of Invasive Breast Cancer WHI Conj. Estrogen + MPA Cumulative Hazards of Invasive Breast Cancer WHI Estrogen only CE+MPA Time, y WHI

More information

OVERVIEW OF MENOPAUSE

OVERVIEW OF MENOPAUSE OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause

More information

Hormone Products for Postmenopausal Use in the United States and Canada

Hormone Products for Postmenopausal Use in the United States and Canada Hormone Products for Postmenopausal Use in the United States and Canada Copyright The North American Menopause Society October 25, 2011 Table 1. Oral ET products for postmenopausal use in the United States

More information

Marco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa University Hospital Italy

Marco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa University Hospital Italy La Terapia Ormonale Sostitutiva in Menopausa: Rivalutazione dei rischi e benefici nell ultimo decennio Marco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa

More information

A Practitioner s Toolkit for the Management of the Menopause

A Practitioner s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash

More information

The preferred treatment for osteoporosis

The preferred treatment for osteoporosis Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the

More information

HRT & Menopause Where Do We Stand Now?

HRT & Menopause Where Do We Stand Now? HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by

More information

Presentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy

Presentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy Presentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy March 5, 2019 Nese Yuksel, BScPharm, PharmD, FCSHP, NCMP Professor Faculty of Pharmacy and Pharmaceutical

More information

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased

More information

Something has changed? The literature from 2008 to present?

Something has changed? The literature from 2008 to present? Something has changed? The literature from 2008 to present? Elina Hemminki National Institute for Health and Welfare, Helsinki, Finland Rome Oct 7, 2011: Post-menopausal hormone therapy and women's information

More information

UPDATE: Women s Health Issues

UPDATE: Women s Health Issues UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial

More information

MENOPAUSAL HORMONE THERAPY 2016

MENOPAUSAL HORMONE THERAPY 2016 MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.

More information

Disclosures. Objec7ves 9/9/15. What Exactly are bio- iden7cal hormones and what should I tell my pa7ents? Christy Blanco, DNP, RN, WHNP- BC.

Disclosures. Objec7ves 9/9/15. What Exactly are bio- iden7cal hormones and what should I tell my pa7ents? Christy Blanco, DNP, RN, WHNP- BC. What Exactly are bio- iden7cal hormones and what should I tell my pa7ents? Christy Blanco, DNP, RN, WHNP- BC Disclosures None Objec7ves Discuss terminology of bio- iden7cal, synthe7c and natural hormones.

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

10/2/2017. The 2017 NAMS Hormone Therapy Position Statement has been endorsed by

10/2/2017. The 2017 NAMS Hormone Therapy Position Statement has been endorsed by 2017 Hormone Therapy Position Statement JoAnn V. Pinkerton, MD, FACOG, NCMP The North American Menopause Society, Executive Director, Professor of Obstetrics and Gynecology Director, Midlife Health Center

More information

LET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy

LET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy THERAPUTIC AGENTS: ARE THEY SAFE? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director of Bone Densitometry

More information

THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY

THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth

More information

22/09/2014. Menopause Management. Menopause. Menopause symptoms

22/09/2014. Menopause Management. Menopause. Menopause symptoms Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):

More information

DINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC

DINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD

More information

Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)

Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures

More information

HT: Where do we stand after WHI?

HT: Where do we stand after WHI? HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women

More information

The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis

The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis Curr Obstet Gynecol Rep (2012) 1:50 58 DOI 10.1007/s13669-012-0007-6 MANAGEMENT OF MENOPAUSE (K-E HUANG, SECTION EDITOR) The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal

More information

What's New in Menopause Management

What's New in Menopause Management Annual Review of Family Medicine December 10, 2015 San Francisco, CA What's New in Menopause Management Michael Policar, MD, MPH Clinical Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine

More information

Difference between vagifem and yuvafem

Difference between vagifem and yuvafem Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone

More information

Menopausal Hormone Therapy

Menopausal Hormone Therapy V FORUM on WOMEN, HEALTH, and GENDER Madrid, October 14-15, 2008 Menopausal Hormone Therapy The Women s Health Initiative (WHI) randomized, placebo-controlled trials Marcia L. Stefanick, Ph.D. Professor

More information

Practical recommendations for hormone replacement therapy in the peri- and postmenopause

Practical recommendations for hormone replacement therapy in the peri- and postmenopause CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David

More information

Federal Judge Sets Trial Dates for Two Hormone Replacement Therapy Cases in Arkansas Thousands More Pending

Federal Judge Sets Trial Dates for Two Hormone Replacement Therapy Cases in Arkansas Thousands More Pending Federal Judge Sets Trial Dates for Two Hormone Replacement Therapy Cases in Arkansas Thousands More Pending Date Published: Sunday, February 12th, 2006 United States District Judge William Wilson in Little

More information

Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services Task Force Recommendation Statement

Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services Task Force Recommendation Statement Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services

More information

Menopause and HRT. John Smiddy and Alistair Ledsam

Menopause and HRT. John Smiddy and Alistair Ledsam Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation

More information

Tissue-selective estrogen complexes for postmenopausal women. BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg

Tissue-selective estrogen complexes for postmenopausal women. BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg Tissue-selective estrogen complexes for postmenopausal women BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg Effects of CEE in Post Menopausal Women with Hysterectomy CHD 0.91 ( 0.75-1.12 ) BC 0.77

More information

HORMONE REPLACEMENT THERAPY

HORMONE REPLACEMENT THERAPY TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors

More information

WARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE

WARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Carole S. Ben-Maimon, M.D. President and Chief Operating Officer One

More information

Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be

Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be made with input from your healthcare provider. After the decision has been made to take HT, many women don t realize

More information

Pearls for Menopause Management: I m ready: now what?

Pearls for Menopause Management: I m ready: now what? Pearls for Menopause Management: I m ready: now what? Friday November 13, 2015 Susan Goldstein MD CCFP FCFP NCMP Assistant Professor Department of Family and Community Medicine University of Toronto Menarche

More information

Hormone therapy. Dr. med. Frank Luzuy

Hormone therapy. Dr. med. Frank Luzuy Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular

More information

Drug Class Review on Hormone Therapy for Postmenopausal Women or Women in the Menopausal Transition Stage

Drug Class Review on Hormone Therapy for Postmenopausal Women or Women in the Menopausal Transition Stage Drug Class Review on Hormone Therapy for Postmenopausal Women or Women in the Menopausal Transition Stage Final Report Update 3 October 2007 Original Report Date: February 2003 Update 1 Report Date: November

More information

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes

More information

GERIATRICS: definitions

GERIATRICS: definitions Caring For The Modern Menopausal Woman in 2016: An Update on Women s Health In the Geriatric Population David J Boes, DO, FACOOG MSU-COM May 2016 What defines the geriatric population???? GERIATRICS: definitions

More information

Evidence Synthesis Number 93

Evidence Synthesis Number 93 Evidence Synthesis Number 93 Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations

More information

The Estrogen Question

The Estrogen Question The Estrogen Question Hormone Therapy still offers the best relief for menopausal symptoms. Is it right for you? When 49-year-old Lee Ann Dodson heard the news that the Women's Health Initiative (WHI)

More information

Current Topics in Hormone Replacement Therapy

Current Topics in Hormone Replacement Therapy Current Topics in Hormone Replacement Therapy Corey R. Babb, D.O., FACOOG, IF, NCMP Clinical Assistant Professor of Obstetrics and Gynecology Director of the Oklahoma State University Center for Women

More information

The North American Menopause Society (NAMS), a

The North American Menopause Society (NAMS), a Menopause: The Journal of The North American Menopause Society Vol. 17, No. 2, pp. 242/255 DOI: 10.1097/gme.0b013e3181d0f6b9 * 2010 by The North American Menopause Society POSITION STATEMENT Estrogen and

More information

BioIdentical Hormone Replacement Therapy for Women

BioIdentical Hormone Replacement Therapy for Women BioIdentical Hormone Replacement Therapy for Women Bio-Identical Hormones are manufactured hormone products from soy or yam. They are changed in a laboratory so that the hormones produced are identical

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

If you would like bypass the presentation for the summary, right click on your mouse and go to slide # 138. Enjoy

If you would like bypass the presentation for the summary, right click on your mouse and go to slide # 138. Enjoy Welcome This is an online version of a presentation given by Dr Keith Merritt. Its purpose is to give a balanced review of the risks, benefits and alternative treatments for the changes and symptoms of

More information

Managing menopause in Primary Care and recent advances in HRT

Managing menopause in Primary Care and recent advances in HRT Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims

More information

Quality of Life. Local Therapy of UG Atrophy. Key Message #1 24/05/2018. Perception of Fears/Problems at Menopause

Quality of Life. Local Therapy of UG Atrophy. Key Message #1 24/05/2018. Perception of Fears/Problems at Menopause Disclosure Menopause Webinar May 24, 2018 Gillian Graves Obs Gyn Dalhousie University Retired No Advisory Boards or other industry relations Guidelines Oversight Committee SOGC Royal College Subspecialty

More information

Estrogens and progestogens

Estrogens and progestogens Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.

More information

Case Presentation. Learning Objectives. Case Presentation. Case Presentation

Case Presentation. Learning Objectives. Case Presentation. Case Presentation Learning Objectives To apply up to date information about the natural history of menopause to improve the care of individual women To counsel women about the risks and benefits of systemic hormone therapy

More information

OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW

OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through

More information

Data Shows Reduction in Frequency and Severity in Hot Flashes in as Early as 14 Days

Data Shows Reduction in Frequency and Severity in Hot Flashes in as Early as 14 Days Newly Published Menopause Study: Bioidentical and FDA Approved Divigel (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated with Menopause Data Shows Reduction

More information

Taking a medicine to reduce the chance of developing breast cancer

Taking a medicine to reduce the chance of developing breast cancer Patient decision aid Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at high risk Published: March 2017 About this decision aid This decision aid

More information

COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center

COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,

More information

All medications are a double-edged sword with risks

All medications are a double-edged sword with risks Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone

More information

Managing menopause in Primary Care and recent advances in HRT

Managing menopause in Primary Care and recent advances in HRT Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway

More information

Financial Conflicts of Interest

Financial Conflicts of Interest Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine

More information

Menopause & HRT. Rosie & Alex. Image:

Menopause & HRT. Rosie & Alex. Image: Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613

More information

Hormone therapy for menopausal vasomotor symptoms

Hormone therapy for menopausal vasomotor symptoms Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert

More information

Her serial lab numbers are as follows: all lipid concentrations in mg/dl

Her serial lab numbers are as follows: all lipid concentrations in mg/dl LIPID CASE 267 Hormones Lipids and Lipoproteins? On to the case: I was asked about the following patient which will lead into a discussion of using menopausal hormone therapies in women with CV risk. A

More information

Management of Menopausal Symptoms

Management of Menopausal Symptoms Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of

More information

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1 Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:

More information

Menopause & HRT. Matt McKenna Elliot Davis

Menopause & HRT. Matt McKenna Elliot Davis Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea

More information

THE SAFETY CHECK LIST BEFORE STARTING HT

THE SAFETY CHECK LIST BEFORE STARTING HT THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by

More information

Centene Pharmacy Therapeutics Committee Therapeutic Class Matrix Summary Table 3Q18

Centene Pharmacy Therapeutics Committee Therapeutic Class Matrix Summary Table 3Q18 HGPI Therapeutic Class Review Recommendation 01 Penicillins Based on the available clinical evidence, there are no utilization management recommendations to be made at this time. 02 Cephalosporins Based

More information

JAMA US Preventive Services Task Force EVIDENCE REPORT

JAMA US Preventive Services Task Force EVIDENCE REPORT Clinical Review & Education JAMA US Preventive Services Task Force EVIDENCE REPORT Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women Evidence Report and Systematic

More information

Hormone therapy. Where are we now? Menopause. Menopause symptoms. Background. Objective. Discussion. Keywords: menopause; hormone therapy

Hormone therapy. Where are we now? Menopause. Menopause symptoms. Background. Objective. Discussion. Keywords: menopause; hormone therapy Menopause Helena J Teede Amanda Vincent Hormone therapy Where are we now? Background Menopause is the permanent cessation of menstruation resulting from loss of ovarian follicular activity. The characteristic

More information

Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure

Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting 2015 Disclosure The faculty and planners for this activity, as well as the CME staff, do not have any relevant

More information

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,

More information

Menopause Matters. Equity Office Staff Seminar 14 November 2018

Menopause Matters. Equity Office Staff Seminar 14 November 2018 Menopause Matters Equity Office Staff Seminar 14 November 2018 1 What to expect at menopause How to manage symptoms Support at work Dr Janice Brown Medical lead, The University of Auckland NZ representative,

More information